Brought to you by 
Acorda to develop Elan oral drug for spinal cord injury
28 Jul 2011
Executive Summary
Acorda Therapeutics (biotech founded 1995 to develop drugs for SCI, spinal cord injury) licensed exclusive worldwide rights to develop Elan's sustained-release oral fampridine (chemical name is 4-aminopyridine, or 4-AP) as an SCI treatment.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acorda to develop Elan oral drug for spinal cord injury
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice